Patents by Inventor John C. McKew

John C. McKew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10017516
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 10, 2018
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit S. Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20170334918
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: ASAF ALIMARDANOV, GREGORY D. CUNY, GURMIT SINGH GREWAL, ARTHUR LEE, JOHN C. MCKEW, AGUSTIN H. MOHEDAS, MIN SHEN, XIN XU, PAUL B. YU
  • Publication number: 20170197968
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: July 14, 2015
    Publication date: July 13, 2017
    Inventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
  • Patent number: 9682983
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 20, 2017
    Assignees: The Brigham and Women's Hospital, Inc., Dept. of Health and Human Services, National Institutes of Health
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit Singh Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20160264570
    Abstract: The invention provides a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula I: wherein A, B, R1, R2, R10, and R11 are described herein, either alone or in combination with a second compound selected from elesclomol, NSC 174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1 152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 15, 2016
    Inventors: John C. McKew, Wei Zheng, Kim C. Williamson, Wenwei Huang, Wei Sun, Takeshi Tanaka, Seameen Jean Dehdashti, Noel Terrence Southall, Crystal Tobin Magle, Xiuli Huang, Paresma Rasiklal Patel, Myunghoon Kim
  • Publication number: 20160046633
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Inventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit Singh Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
  • Publication number: 20150031693
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.
    Type: Application
    Filed: November 2, 2012
    Publication date: January 29, 2015
    Applicant: AFRAXIS HOLDINGS, INC.
    Inventors: John C. Mckew, Wenwei Huang, David Campbell, Sergio G. Durön, Mark Behnke, Min Shen
  • Patent number: 8283373
    Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: October 9, 2012
    Assignee: Pfizer Inc.
    Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Patent number: 7906548
    Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: March 15, 2011
    Assignee: Wyeth LLC
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Patent number: 7713964
    Abstract: This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: May 11, 2010
    Assignee: Wyeth LLC
    Inventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Publication number: 20100035957
    Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Publication number: 20100029645
    Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.
    Type: Application
    Filed: June 19, 2009
    Publication date: February 4, 2010
    Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Publication number: 20100029648
    Abstract: This invention relates to inhibiting 11?HSD1.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 4, 2010
    Inventors: Jason Shaoyun Xiang, Eddine Saiah, Steve Y. Tam, John C. McKew, Lihren Chen, Manus Ipek, Katherine Lee, Huan-Qiu Li, Jianchang Li, Wei Li, Tarek Suhayl Mansour, Vipin Suri, Richard Vargas, Yuchuan Wu, Zhao-Kui Wan, Jinbo Lee, Eva Binnun, Douglas P. Wilson
  • Publication number: 20100022536
    Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 28, 2010
    Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Patent number: 7632838
    Abstract: This invention relates to inhibiting 11?HSD1.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: December 15, 2009
    Assignee: Wyeth
    Inventors: Jason Shaoyun Xiang, Eddine Saiah, Steve Y. Tam, John C. Mckew, Lihren Chen, Manus Ipek, Huan-Qiu Li, Jianchang Li, Wei Li, Tarek Suhayl Mansour, Vipin Suri, Yuchuan Wu, Zhao-Kui Wan, Jinbo Lee, Eva Binnun, Douglas P. Wilson
  • Patent number: 7605156
    Abstract: This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: October 20, 2009
    Assignee: Wyeth
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark L. Behnke, Baihua Hu, James D. Clark, Wei Li, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Patent number: 7557135
    Abstract: This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2?). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: July 7, 2009
    Assignee: Wyeth
    Inventors: John C. McKew, Katherine L. Lee, Lihren Chen, Richard Vargas, James D. Clark, Cara Williams, Valerie Clerin, Suzana Marusic, Kevin Pong
  • Patent number: 7101875
    Abstract: This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 5, 2006
    Assignee: Wyeth
    Inventors: John C. McKew, Steve Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Patent number: 6984735
    Abstract: A process for making an aromatic aldehyde in which a sulfoxide is reacted with a dihalogenated aromatic compound in the absence of an effective amount of an activating reagent. The aldehyde may then be used to make other compounds, such as a compound that acts as a cPLA inhibitor.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: January 10, 2006
    Assignee: Wyeth
    Inventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark, Wei Li
  • Patent number: 6916841
    Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: July 12, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Jasbir S. Seehra, Neelu Kaila, John C. McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang